Table 1 Clinical and demographic characteristics of SSc patients. Clinical and demographic features od enrolled SSc patients affected and no-affected by interstitial lung diseases (SSc-ILD pts and SSc pts no-ILD, respectively). Reported data include age, sex (F/M), disease duration, auto-antibody profile, organ involvement, and therapy. SSc patients without ILD are not displayed in this table
| Â | SSc-ILD pts | SSc pts no-ILD |
|---|---|---|
Clinical and demographic features | Values | Values |
Number of patients | 10 | 4 |
Mean age (years) | 63.6±14.0 | 64.7±9.4 |
Gender (F/M) | 7/3 | 4/0 |
Smokers (n°) | 5 | 2 |
Mean disease duration ± standard deviation (years) | 7.2±5.1 | 14.75±5.91 |
Scl70 (n°) | 5 | 1 |
CENP-A/B (n°) | 2 | 0 |
RNA poly I-III (n°) | 0 | 0 |
Others (n°) | 3 | 0 |
Raynaud’s phenomenon (n°) | 10 | 3 |
Skin involvement (lcSSc / dcSSc) (n°) | 5/ 5 | 2/2 |
Previous DUs (n°) | 6 | 2 |
Active DUs (n°) | 4 | 1 |
mRSS (mean± standard deviation) | 8.7±6.68 | 6.11±4.84 |
FVC | 89.7% ± 32.5 | 86,38% ± 24,13 |
FEV1 | 87.7% ± 27.5 | 86.95% ± 27 |
DLCO | 66.7% ± 28.8 | 68.3% ± 21.26 |
PAH (n°) | 0 | 1 |
Gastrointestinal involvement (n°) | 4 | 4 |
Kidney involvement (n°) | 1 | 0 |
Therapy (n°) | MMF = 5 | MMF = 0 |
|  | MTX = 1 | MTX = 0 |
|  | RTX = 2 | RTX = 0 |
|  | AZA = 0 | AZA = 0 |
|  | CYC = 0 | CYC = 3 |
|  | PDN = 4 | PDN = 0 |
|  | HCQ = 2 | HCQ = 1 |
|  | Ca-ant = 3 | Ca-ant = 2 |
|  | PDE5i = 1 | PDE5i = 2 |
|  | ERA = 4 | ERA = 1 |
|  | Prostanoids = 4 | Prostanoids = 1 |
|  | Selexipag = 0 | Selexipag = 0 |
|  | Riociguat = 0 | Riociguat = 0 |
|  | ACEi = 5 | ACEi = 2 |